Today Wedbush Maintains a Buy Rating on Miragen Therapeutics Inc (MGEN) and a $19.0000 Target Price

June 8, 2018 - By Richard Conner

Miragen Therapeutics Inc (MGEN) Rating Reaffirmed

In a note sent to investors and clients on Thursday, 7 June, The Buy rating of Miragen Therapeutics Inc (MGEN) shares was reiterated by Wedbush, who now has a $19.0000 TP on the stock. Wedbush’s TP means a possible upside of 155.38 % from the current stock price of the company.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering miRagen Therapeutics Inc (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. miRagen Therapeutics Inc has $19 highest and $1300 lowest target. $16.29’s average target is 118.95% above currents $7.44 stock price. miRagen Therapeutics Inc had 19 analyst reports since January 4, 2018 according to SRatingsIntel. FBR Capital maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Friday, February 2 with “Buy” rating. As per Thursday, May 17, the company rating was maintained by FBR Capital. FBR Capital maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Thursday, March 15 with “Buy” rating. Oppenheimer initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Tuesday, March 27 with “Buy” rating. FBR Capital maintained the shares of MGEN in report on Thursday, May 10 with “Buy” rating. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by Oppenheimer on Thursday, January 11. The company was maintained on Tuesday, March 20 by Wedbush. The rating was maintained by FBR Capital with “Buy” on Monday, June 4. Wedbush maintained it with “Buy” rating and $1900 target in Monday, April 23 report. The firm earned “Buy” rating on Wednesday, March 28 by Wedbush.

The stock decreased 0.67% or $0.05 during the last trading session, reaching $7.44. About 145,017 shares traded. Miragen Therapeutics, Inc. (MGEN) has declined 34.18% since June 8, 2017 and is downtrending. It has underperformed by 46.75% the S&P500.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on August, 10. They expect $-0.29 earnings per share, up 14.71 % or $0.05 from last year’s $-0.34 per share. After $-0.18 actual earnings per share reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 61.11 % negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $224.63 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More important recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: which released: “miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” on May 09, 2018, also published article titled: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines”, published: “miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th” on May 18, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) was released by: and their article: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: